Tonix Pharmaceuticals Files 8-K with Presentations

Ticker: TNXP · Form: 8-K · Filed: Mar 31, 2026 · CIK: 0001430306

Tonix Pharmaceuticals Holding Corp. 8-K Filing Summary
FieldDetail
CompanyTonix Pharmaceuticals Holding Corp. (TNXP)
Form Type8-K
Filed DateMar 31, 2026
Risk Levelmedium
Pages4
Reading Time4 min
Sentimentneutral

Sentiment: neutral

Topics: regulation-fd, corporate-presentation, filing-update

Related Tickers: TNXP

TL;DR

TNXP dropped an 8-K with new presentations on 3/31 - check for updates.

AI Summary

Tonix Pharmaceuticals Holding Corp. filed an 8-K on March 31, 2026, reporting on events from March 30, 2026. The filing includes a press release and corporate presentations, indicating potential new information or updates being shared with the public. Specific details regarding the content of these presentations or the nature of the events are not elaborated upon in the filing's summary information.

Why It Matters

This filing suggests Tonix Pharmaceuticals may be disclosing new information or strategic updates to investors and the public, which could impact its stock performance.

Risk Assessment

Risk Level: medium — The filing indicates new information is being released, but the lack of specific details in the summary requires further investigation to assess the impact.

Key Players & Entities

  • Tonix Pharmaceuticals Holding Corp. (company) — Filer of the 8-K report
  • 0001430306 (company) — CIK number for Tonix Pharmaceuticals Holding Corp.
  • 0001999371-26-007254 (filing_id) — SEC Accession Number for the 8-K filing
  • 2026-03-31 (date) — Filing Date and Acceptance Date of the 8-K
  • 2026-03-30 (date) — Period of Report for the 8-K

FAQ

What specific information is disclosed in the press release and corporate presentations?

The filing does not provide specific details on the content of the press release (EX-99.01) or the corporate presentations (EX-99.02, EX-99.03) within the summary information, only that they are included as exhibits.

What is the purpose of filing Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events)?

Item 7.01 indicates that information is being disclosed under Regulation FD, meaning it's non-public material information being shared broadly. Item 8.01 covers other events that the company deems material to report.

Are there any financial statements included in this filing?

No, the filing lists Item 9.01 as 'Financial Statements and Exhibits,' but the documents listed are primarily the 8-K itself, a press release, and presentations, not financial statements.

What is the significance of the multiple graphic files listed?

The numerous graphic files (e.g., ex9902_01.jpg) are likely visual aids or charts from the corporate presentations, intended to supplement the information presented.

When was the information in the report period (March 30, 2026) intended to be communicated?

The filing date is March 31, 2026, and the report period is March 30, 2026, suggesting the information was prepared or finalized around March 30th and filed the next day.

Filing Stats: 1,117 words · 4 min read · ~4 pages · Grade level 11.9 · Accepted 2026-03-31 07:05:34

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On March 31, 2026, Tonix Pharmaceuticals Holding Corp. (the "Company") announced program updates on its TNX-4800 (formerly known as mAb 2217LS) product candidate for protection against Lyme disease. A copy of the press release that discusses these matters is furnished hereto as Exhibit 99.01, and is incorporated herein by reference. Copies of presentations that discuss these matters are furnished hereto as Exhibits 99.02 and 99.03, and are incorporated herein by reference. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.01, 99.02 and 99.03 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the United States Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01

Item 8.01 Other Events. On March 31, 2026, the Company announced program updates on its TNX-4800 product candidate for protection against Lyme disease, including the announcement that Phase 1 data of TNX-4800 was presented by Mark S. Klempner, MD, professor of medicine at UMass Chan Medical School, an inventor of TNX-4800 and principal investigator of the study, on March 30, 2026, at the World Vaccine Congress Washington 2026. The Company also announced its strategy for a Phase 2 field study of TNX-4800, expected to initiate in the first half of 2027, pending U.S. Food and Drug Administration (" FDA") clearance. The Company intends to study TNX-4800 in a randomized, double-blind, placebo-controlled, adaptive Phase 2 field study to evaluate the efficacy of a single subcutaneous dose of TNX-4800, 350 mg, in preventing the first occurrence of confirmed Lyme disease during the primary efficacy surveillance period (Day 3 through Month 4 following administration). A fixed dose of 350 mg was selected for the Phase 2 field study based on Phase 1 pharmacokinetic data, which dose (i) is expected to provide exposures comparable to the 5 mg/kg dose evaluated in the Phase 1 study and (ii) resulted in mean blood levels of 10 g/ml at four months. Participants will include adolescents and adults 16 to 65 years of age in Lyme-endemic areas in the U.S. The primary endpoint will be the prevention of Lyme disease at four months (comparison of TNX-4800 group and placebo group). The key secondary endpoint will be the prevention of Lyme disease at six months (comparison of TNX-4800 vs. placebo). The Company expects to have GMP investigational product available for clinical testing in early 2027. Additionally, if necessary and pending FDA clearance, the Company plans to initiate a controlled human infection model study in 2028. The charts below set forth certain data from the Phase 1 trial for TNX-4800. Observed Phase 1 Pharmacokinetics TNX-4800 Phase 1: Variability of Serum Conce

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines and approvals and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which the Company operates and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibit No. Description. 99.01 Press Release of the Company, March 31, 2026 99.02 Corporate Presentation, March 31, 2026 99.03 Presentation, March 30, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. TONIX PHARMACEUTICALS HOLDING CORP. Date: March 31, 2026 By: /s/ Bradley Saenger Bradley Saenger Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.